Lakewood-Amedex Reports Low Resistance Development for Novel Antimicrobial Nu-3 in Diabetic Foot Ulcer Treatment
核心洞察
Lakewood-Amedex Biotherapeutics (搜索) announced positive antimicrobial resistance data for Nu-3, a novel Bisphosphocin compound being developed for infected diabetic foot ulcers.
Laboratory studies showed Nu-3 maintained low resistance development over 21 days, with minimal MIC increases compared to ciprofloxacin's over 2,000-fold resistance increase.
The compound demonstrated no cross-resistance with ciprofloxacin-resistant bacteria and rapid bactericidal activity within one minute through bacterial membrane disruption.
Lakewood-Amedex Biotherapeutics (搜索) has reported promising antimicrobial resistance data for Nu-3, its lead compound targeting infected diabetic foot ulcers (iDFU), demonstrating significantly lower resistance development compared to conventional antibiotics in laboratory studies.
Novel Mechanism Shows Resistance Advantage
Nu-3 belongs to the Bisphosphocin class of antimicrobials, which rapidly kill bacteria through pH and concentration-dependent destabilization of bacterial cell membranes, typically achieving bactericidal effects within one minute of exposure. This mechanism offers potential advantages against antibiotic-resistant strains including methicillin-resistant staphylococcus aureus (MRSA (搜索)) and vancomycin-resistant enterococci (VRE (搜索)).
In 21-day laboratory studies using serial passage of E. coli and MRSA (搜索) in the presence of Nu-3, the compound showed only slight increases in minimum inhibitory concentration (MIC) for E. coli and no changes for MRSA. In stark contrast, ciprofloxacin's MIC increased over 2,000-fold for E. coli and more than 600-fold for MRSA under similar conditions.
Cross-Resistance Testing Results
Notably, Nu-3 maintained its original MIC when tested against bacteria that had developed resistance to ciprofloxacin, suggesting no cross-resistance between the compounds. This finding supports the distinct mechanism of action of the Bisphosphocin class compared to conventional antibiotics.
"In experiments designed to induce resistance, the Bisphosphocin class has maintained its in vitro efficacy and potency, demonstrating a very low potential for resistance development," said Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics (搜索). "This confers enormous potential for our Nu-3 candidate targeting iDFU, and more broadly, as we work towards solutions for antimicrobial resistance, a major health challenge for our society."
Addressing Critical Medical Need
The development addresses a significant healthcare challenge, as approximately 830 million people globally suffer from diabetes, with about one-third developing diabetic foot ulcers during their lifetime. Of these, approximately 50% become infected, with many patients experiencing multiple infection events.
"Drug-resistant pathogens are a rising threat that have rendered many existing antibiotics ineffective, leading to increased mortality as well as higher healthcare costs and longer hospital stays," stated Thomas Balzer, Chief Medical Officer and Senior Vice President of Clinical Development. "We are developing Nu-3 to meet this very large, critically underserved treatment need."
Clinical and Economic Impact
About 15% to 20% of iDFU cases are caused by resistant pathogens, primarily MRSA (搜索), underscoring the need for rapid and effective treatment to prevent disease progression and potentially devastating complications like amputations. The global antimicrobial resistance crisis is directly responsible for approximately 1.27 million deaths annually and contributes to nearly 5 million deaths worldwide.
The economic burden of diabetic foot ulcer complications is substantial, with care costs estimated at $80 billion in 2018 in the United States alone, comparable to treating the five most expensive forms of cancer combined.
Broader Development Pipeline
Beyond iDFU treatment, Lakewood-Amedex is exploring the Bisphosphocin class in pre-clinical studies for complicated urinary tract infections and pulmonary infections, potentially expanding the therapeutic applications of this novel antimicrobial approach.